StockData
IN8bio, Inc. logo

IN8bio, Inc. (INAB) stock

INABNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.82+0.00 (+0.49%)

Close on Nov 17, 2026Market cap $8.08MP/E –Yield –

IN8bio cash

Cash and short-term investments held at the end of each period.

IN8bio's cash was $17.96M at Jun 30, 2026. For fiscal 2025 it was $27.09M, up 137.9% from the year before. The highest annual figure on record is $37.27M in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$27.09M+137.9%
FY2024Dec 31, 2024$11.39M-47.1%
FY2023Dec 31, 2023$21.54M+16.8%
FY2022Dec 31, 2022$18.43M-50.5%
FY2021Dec 31, 2021$37.27M+105.5%
FY2020Dec 31, 2020$18.14M+2314.8%
FY2019Dec 31, 2019$751.00K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$17.96M+35.8%
Q1 FY2026Mar 31, 2026$21.94M+84.6%
Q4 FY2025Dec 31, 2025$27.09M+137.9%
Q3 FY2025Sep 30, 2025$10.69M+167.2%
Q2 FY2025Jun 30, 2025$13.23M+29.5%
Q1 FY2025Mar 31, 2025$11.89M-8.7%
Q4 FY2024Dec 31, 2024$11.39M-47.1%
Q3 FY2024Sep 30, 2024$4.00M-68.9%
Q2 FY2024Jun 30, 2024$10.22M-39.9%
Q1 FY2024Mar 31, 2024$13.02M+19.8%
Q4 FY2023Dec 31, 2023$21.54M+16.8%
Q3 FY2023Sep 30, 2023$12.85M-53.5%
Q2 FY2023Jun 30, 2023$16.99M-34.0%
Q1 FY2023Mar 31, 2023$10.86M-66.2%
Q4 FY2022Dec 31, 2022$18.43M-50.5%
Q3 FY2022Sep 30, 2022$27.65M-31.6%
Q2 FY2022Jun 30, 2022$25.74M+114.5%
Q1 FY2022Mar 31, 2022$32.11M+113.3%
Q4 FY2021Dec 31, 2021$37.27M+105.5%
Q3 FY2021Sep 30, 2021$40.42M+95.6%
Q2 FY2021Jun 30, 2021$12.00M+277.3%
Q1 FY2021Mar 31, 2021$15.05M+1904.3%
Q4 FY2020Dec 31, 2020$18.14M–
Q3 FY2020Sep 30, 2020$20.67M–
Q2 FY2020Jun 30, 2020$3.18M–
Q4 FY2019Dec 31, 2019$751.00K–

More IN8bio figures

See a number that looks wrong?